An anonymous reader quotes a report from ScienceAlert: [A] team of surgeons has successfully completed the first human implantation in the US of an artificial heart device called the ‘Aeson’, developed by French company CARMAT. The artificial heart has two ventricular chambers and four biological valves, just like the real organ, and is powered by an external device. Made from “biocompatible materials” including bovine tissue, the artificial heart uses a combination of sensors and algorithms to maintain its pace and keep blood circulating through the body. “We are encouraged that our patient is doing so well after the procedure,” says cardiologist Carmelo Milano from the Duke University School of Medicine. “As we evaluate this device, we are both excited and hopeful that patients who otherwise have few to no options could have a lifeline.” The patient in question is 39-year-old Matthew Moore, from Shallotte in North Carolina. Moore was initially due to have heart bypass surgery, but as his condition deteriorated the medical staff started to run out of options; he became so ill that even a regular heart transplant was too risky. Fortunately, he was in the right place: the Aeson device is being tested at Duke University, pending approval from the US Food and Drug Administration (FDA). It’s already been given the green light for use by regulators in Europe, after several years of tests in European patients, not all of which have been successful. The artificial heart has been developed specifically to help those whose hearts can no longer pump enough blood through both chambers. It replaces the entire natural heart, although it’s not intended to be permanent — it’s designed to be a bridge towards a full heart transplant within six months or so. Read more of this story at Slashdot.